fortress
biotech
announces
initiation
phase
studies
al
amyloidosis
caelum
biosciences
company
founded
fortress
collaborating
alexion
pharmaceuticals
studies
phase
study
met
primary
objective
supporting
initiation
two
parallel
phase
studies
enroll
al
amyloidosis
patients
positive
phase
data
presented
international
symposium
amyloidosis
isa
demonstrate
prolonged
overall
survival
percent
months
durable
organ
response
new
york
globe
newswire
fortress
biotech
nasdaq
fbio
fortress
innovative
company
focused
acquiring
developing
commercializing
monetizing
promising
biopharmaceutical
products
product
candidates
today
announced
caelum
biosciences
caelum
collaboration
alexion
pharmaceuticals
alexion
initiated
cardiac
amyloid
reaching
extended
survival
cares
phase
clinical
program
evaluate
amyloid
fibril
targeted
therapy
combination
soc
therapy
al
amyloidosis
caelum
company
founded
fortress
entered
collaboration
agreement
alexion
alexion
acquired
minority
equity
interest
caelum
exclusive
option
acquire
remaining
equity
company
based
phase
data
fortress
maintains
percent
ownership
caelum
issued
outstanding
stock
eligible
receive
approximately
percent
proceeds
alexion
acquisition
option
exercise
pleased
progressed
phase
development
said
lindsay
rosenwald
chairman
president
chief
executive
officer
fortress
potential
fill
urgent
need
new
treatment
options
patients
al
amyloidosis
data
thus
far
suggest
may
improve
organ
function
overall
survival
partnership
caelum
alexion
represents
exciting
opportunity
help
patients
create
value
shareholders
look
forward
continued
development
important
cares
clinical
program
includes
two
parallel
phase
studies
one
patients
mayo
stage
iiia
disease
one
patients
mayo
stage
iiib
disease
collectively
enroll
approximately
patients
globally
enrollment
underway
studies
primary
objective
clinical
program
assess
overall
survival
al
amyloidosis
also
called
primary
amyloidosis
rare
disease
occurs
abnormal
protein
called
amyloid
builds
organs
interferes
normal
function
affects
many
organs
including
heart
kidneys
causes
significant
damage
impairs
organ
function
median
survival
patients
al
amyloidosis
affected
heart
less
year
following
diagnosis
cares
phase
clinical
program
cares
clinical
program
consists
two
parallel
randomized
global
phase
studies
evaluating
efficacy
safety
al
amyloidosis
patients
newly
diagnosed
na√Øve
standard
care
soc
treatment
cybord
chemotherapy
one
study
enrolling
approximately
patients
mayo
stage
iiia
disease
one
study
enrolling
approximately
patients
mayo
stage
iiib
disease
studies
conducted
approximately
sites
across
north
america
united
kingdom
europe
israel
japan
australia
study
participants
randomized
ratio
receive
either
plus
soc
placebo
plus
soc
weekly
four
weeks
followed
maintenance
dose
administered
every
two
weeks
last
patient
enrolled
completes
least
weeks
treatment
patients
continue
visits
every
weeks
primary
study
objectives
overall
survival
safety
tolerability
key
secondary
objectives
assess
functional
improvement
walk
test
quality
life
measures
kansas
city
cardiomyopathy
questionnaire
overall
score
short
form
version
physical
component
score
cardiac
improvement
global
longitudinal
strain
gls
phase
study
results
phase
dose
escalation
study
conducted
investigate
higher
doses
evaluated
phase
studies
primary
objective
identify
best
dose
advance
phase
development
study
evaluated
safety
tolerability
al
amyloidosis
patients
three
study
sites
received
mg
two
times
phase
dose
administered
combination
soc
treatment
study
met
primary
objectives
supporting
safety
tolerability
selection
mg
dose
phase
study
phase
results
presented
international
symposium
amyloidosis
previously
reported
phase
study
first
clinical
trial
demonstrate
improvement
cardiac
function
via
gls
treatment
amyloid
fibril
targeted
therapy
al
amyloidosis
patients
amyloid
cardiac
involvement
new
data
phase
study
presented
virtual
international
symposium
amyloidosis
isa
september
poster
titled
long
term
patients
al
amyloidosis
treated
phase
study
monoclonal
antibody
abstract
divaya
bhutani
et
al
columbia
university
medical
center
data
demonstrate
percent
survival
median
three
years
months
al
amyloidosis
patients
treated
well
durable
organ
response
among
evaluable
patients
supporting
advancement
phase
development
monoclonal
antibody
mab
designed
improve
organ
function
reducing
eliminating
amyloid
deposits
tissues
organs
patients
al
amyloidosis
antibody
designed
bind
misfolded
light
chain
protein
amyloid
shows
binding
kappa
lambda
subtypes
phase
study
demonstrated
improved
organ
function
including
cardiac
renal
function
patients
relapsed
refractory
al
amyloidosis
previously
organ
response
standard
care
therapy
received
orphan
drug
designation
food
drug
administration
european
medicines
agency
therapy
patients
al
amyloidosis
al
amyloidosis
al
amyloidosis
rare
systemic
disorder
caused
abnormality
plasma
cells
bone
marrow
misfolded
immunoglobulin
light
chains
produced
plasma
cells
aggregate
form
fibrils
deposit
tissues
organs
deposition
cause
widespread
progressive
organ
damage
high
mortality
rates
death
frequently
occurring
result
cardiac
failure
current
standard
care
includes
plasma
cell
directed
chemotherapy
autologous
stem
cell
transplant
therapies
address
organ
dysfunction
caused
amyloid
deposition
percent
patients
ineligible
transplant
al
amyloidosis
rare
disease
common
form
amyloidosis
approximately
patients
across
united
states
france
germany
italy
spain
united
kingdom
al
amyloidosis
mortality
rate
percent
percent
caused
cardiac
amyloidosis
caelum
biosciences
caelum
biosciences
caelum
biotechnology
company
developing
treatments
rare
diseases
caelum
lead
asset
novel
antibody
treatment
patients
amyloid
light
chain
al
amyloidosis
caelum
entered
collaboration
agreement
alexion
alexion
acquired
minority
equity
interest
caelum
exclusive
option
acquire
remaining
equity
company
based
phase
data
caelum
founded
fortress
biotech
nasdaq
fbio
information
visit
fortress
biotech
fortress
biotech
fortress
innovative
biopharmaceutical
company
recently
ranked
number
deloitte
technology
fast
annual
ranking
north
american
companies
technology
media
telecommunications
life
sciences
energy
tech
sectors
based
percentage
fiscal
year
revenue
growth
period
fortress
focused
acquiring
developing
commercializing
marketed
drugs
drug
candidates
company
five
marketed
prescription
pharmaceutical
products
programs
development
fortress
partners
partners
founded
holds
significant
minority
ownership
positions
product
candidates
span
six
areas
including
oncology
rare
diseases
gene
therapy
allow
create
value
shareholders
fortress
advances
diversified
pipeline
streamlined
operating
structure
fosters
efficient
drug
development
fortress
model
driven
business
development
team
focused
leveraging
significant
biopharmaceutical
industry
expertise
expand
company
portfolio
product
opportunities
fortress
established
partnerships
world
leading
academic
research
institutions
biopharmaceutical
companies
maximize
opportunity
full
potential
including
alexion
pharmaceuticals
astrazeneca
city
hope
fred
hutchinson
cancer
research
center
invagen
pharmaceuticals
subsidiary
cipla
limited
jude
children
research
hospital
nationwide
children
hospital
information
visit
statement
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
used
throughout
press
release
words
us
may
refer
fortress
individually
together
one
partner
companies
dictated
context
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
price
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
uncertainties
relating
preclinical
clinical
testing
risks
relating
timing
starting
completing
clinical
trials
dependence
suppliers
risks
relating
outbreak
potential
impact
employees
consultants
ability
complete
work
timely
manner
ability
obtain
additional
financing
favorable
terms
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
securities
exchange
commission
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
may
required
law
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
information
contained
herein
intended
reviewed
totality
stipulations
conditions
provisos
apply
given
piece
information
one
part
press
release
read
applying
mutatis
mutandis
every
instance
information
appearing
herein
company
contacts
jaclyn
jaffe
william
begien
investor
relations
ir
michael
spector
president
chief
executive
officer
caelum
biosciences
mspector
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
media
relations
contact
tony
plohoros
degrees
tplohoros
